1-12 of 12
Ronald M. Bukowski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A54: Potential mechanisms of resistance to targeted agents in human clear cell renal cell carcinoma

Free
Adrian G. Grozav, Susan A.J. Vaziri, Koegle R. Eric, Dale R. Grabowski, Ronald M. Bukowski, Mahrukh K. Ganapathi, Ram N. Ganapathi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): A54.
https://doi.org/10.1158/1078-0432.MECHRES-A54
Published: 04 March 2013
View articletitled, Abstract A54: Potential mechanisms of resistance to targeted agents in human clear cell renal cell carcinoma
Open the PDF for Abstract A54: Potential mechanisms of resistance to targeted agents in human clear cell renal cell carcinoma in another window
Journal Articles

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Available to Purchase
Carol Peña, Chetan Lathia, Minghua Shan, Bernard Escudier, Ronald M. Bukowski
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19): 4853–4863.
https://doi.org/10.1158/1078-0432.CCR-09-3343
Published: 29 September 2010
View articletitled, Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Open the PDF for Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial in another window
Journal Articles

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Available to Purchase
Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski, Thomas J. Lynch, Pamela N. Munster, Geoffrey I. Shapiro, Pasi A. Jänne, Joseph P. Eder, Michael J. Naughton, Matthew J. Ellis, Suzanne F. Jones, Tarek Mekhail, Charles Zacharchuk, Jennifer Vermette, Richat Abbas, Susan Quinn, Christine Powell, Howard A. Burris
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2552–2558.
https://doi.org/10.1158/1078-0432.CCR-08-1978
Published: 01 April 2009
View articletitled, A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
Open the PDF for A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors in another window
Journal Articles

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Weekly Paclitaxel in Patients with Solid Tumors

Available to Purchase
Neal E. Ready, Alan Lipton, Yali Zhu, Paul Statkevich, Emily Frank, Dolores Curtis, Ronald M. Bukowski
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 576–583.
https://doi.org/10.1158/1078-0432.CCR-06-1262
Published: 25 January 2007
View articletitled, Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Weekly Paclitaxel in Patients with Solid Tumors
Open the PDF for Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Weekly Paclitaxel in Patients with Solid Tumors in another window
Journal Articles

Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma

Available to Purchase
Christopher J. Herrem, Tomohide Tatsumi, Kathleen S. Olson, Keisuke Shirai, James H. Finke, Ronald M. Bukowski, Ming Zhou, Amy L. Richmond, Ithaar Derweesh, Michael S. Kinch, Walter J. Storkus
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (1): 226–231.
https://doi.org/10.1158/1078-0432.226.11.1
Published: 21 January 2005
View articletitled, Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma
Open the PDF for Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma in another window
Journal Articles

Innovations and Challenges in Renal Cancer: Consensus Statement from the First International Conference

Available to Purchase
Michael B. Atkins, David E. Avigan, Ronald M. Bukowski, Richard W. Childs, Janice P. Dutcher, Tim G. Eisen, Robert A. Figlin, James H. Finke, Robert C. Flanigan, Daniel J. George, S. Nahum Goldberg, Michael S. Gordon, Othon Iliopoulos, William G. Kaelin, Jr., W. Marston Linehan, Allan Lipton, Robert J. Motzer, Andrew C. Novick, Walter M. Stadler, Bin Tean Teh, James C. Yang, Laura King
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6277S–6281S.
https://doi.org/10.1158/1078-0432.CCR-040720
Published: 15 September 2004
View articletitled, Innovations and Challenges in Renal Cancer: Consensus Statement from the First International Conference
Open the PDF for Innovations and Challenges in Renal Cancer: Consensus Statement from the First International Conference in another window
Journal Articles

Skeletal Complications in Patients with Bone Metastases from Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic Acid

Available to Purchase
Allan Lipton, Alejandro Colombo-Berra, Ronald M. Bukowski, Lee Rosen, Ming Zheng, Gladys Urbanowitz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6397S–6403S.
https://doi.org/10.1158/1078-0432.CCR-040030
Published: 15 September 2004
View articletitled, Skeletal Complications in Patients with Bone Metastases from Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic Acid
Open the PDF for Skeletal Complications in Patients with Bone Metastases from Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic Acid in another window
Journal Articles

Prognostic Factors in Patients with Advanced Renal Cell Carcinoma: Development of an International Kidney Cancer Working Group

Available to Purchase
Ronald M. Bukowski, Sylvie Negrier, Paul Elson
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6310S–6314S.
https://doi.org/10.1158/1078-0432.CCR-050000
Published: 15 September 2004
View articletitled, Prognostic Factors in Patients with Advanced Renal Cell Carcinoma: Development of an International Kidney Cancer Working Group
Open the PDF for Prognostic Factors in Patients with Advanced Renal Cell Carcinoma: Development of an International Kidney Cancer Working Group in another window
Journal Articles

Phase I Trial of Consensus Interferon in Patients with Metastatic Renal Cell Carcinoma: Toxicity and Immunological Effects

Available to Purchase
Thomas E. Hutson, Luis Molto, Tarek Mekhail, Paul Elson, James Finke, Charles Tannenbaum, Ernest Borden, Robert Dreicer, Thomas Olencki, Ronald M. Bukowski
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (4): 1354–1360.
Published: 01 April 2003
View articletitled, Phase I Trial of Consensus Interferon in Patients with Metastatic Renal Cell Carcinoma: Toxicity and Immunological Effects
Open the PDF for Phase I Trial of Consensus Interferon in Patients with Metastatic Renal Cell Carcinoma: Toxicity and Immunological Effects in another window
Journal Articles

MAGE-6 Encodes HLA-DRβ1*0401-presented Epitopes Recognized by CD4+ T Cells from Patients with Melanoma or Renal Cell Carcinoma

Available to Purchase
Tomohide Tatsumi, Lisa S. Kierstead, Elena Ranieri, Loreto Gesualdo, Francesco P. Schena, James H. Finke, Ronald M. Bukowski, Vladimir Brusic, John Sidney, Alessandro Sette, Theodore F. Logan, Yvette L. Kasamon, Craig L. Slingluff, Jr., John M. Kirkwood, Walter J. Storkus
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (3): 947–954.
Published: 01 March 2003
View articletitled, MAGE-6 Encodes HLA-DRβ1*0401-presented Epitopes Recognized by CD4+ T Cells from Patients with Melanoma or Renal Cell Carcinoma
Open the PDF for MAGE-6 Encodes HLA-DRβ1*0401-presented Epitopes Recognized by CD4+ T Cells from Patients with Melanoma or Renal Cell Carcinoma in another window
Journal Articles

Tumor-induced Sensitivity to Apoptosis in T Cells from Patients with Renal Cell Carcinoma: Role of Nuclear Factor-κB Suppression

Available to Purchase
James H. Finke, Patricia Rayman, Roshini George, Charles S. Tannenbaum, Vladimir Kolenko, Robert Uzzo, Andrew C. Novick, Ronald M. Bukowski
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (3): 940s–946s.
Published: 01 March 2001
View articletitled, Tumor-induced Sensitivity to Apoptosis in T Cells from Patients with Renal Cell Carcinoma: Role of Nuclear Factor-κB Suppression
Open the PDF for Tumor-induced Sensitivity to Apoptosis in T Cells from Patients with Renal Cell Carcinoma: Role of Nuclear Factor-κB Suppression in another window
Journal Articles

Interferon-γ and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma

Available to Purchase
Ronald M. Bukowski, Patricia Rayman, Luis Molto, Charles S. Tannenbaum, Thomas Olencki, David Peereboom, Raymond Tubbs, Denise McLain, G. Thomas Budd, Thomas Griffin, Andrew Novick, Thomas A. Hamilton, James Finke
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (10): 2780–2789.
Published: 01 October 1999
View articletitled, Interferon-γ and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma
Open the PDF for Interferon-γ and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma in another window